Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers
The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called the miR Sentinel Prostate Test, to alleviate the burden of prostate cancer in the U.S. territory. Prostate cancer is the most common form of cancer and the most common cause of cancer death among men in Puerto Rico, prompting ASES to consider new ways of combatting the disease. "The prevalence and economic burden of prostate cancer in Puerto Rico are debilitating and the Puerto Rico government is keen on deploying the most innovative solutions in the fight against prostate cancer," Jorge Galva, executive director of ASES, said in a press release. Current methods of prostate cancer detection rely on blood tests, which screen for the protein prostate-specific antigen (PSA), or on digital rectal exams. Following these initial tests, an invasive process — a biopsy of the prostate — is often taken to confirm the diagnosis. The miR Sentinel Prostate Test is an investigative, non-invasive technique reported to be able to not only detect prostate c
Subscribe or to access all post and page content.